Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia

Blood

Volumn 112, Issue 8, 2008, Pages 3135-3137

  Carobbio, Alessandra ^a   Finazzi, Guido ^a   Antonioli, Elisabetta ^b   Guglielmelli, Paola ^b   Vannucchi, Alessandro M ^b   Delaini, Federica ^a   Guerini, Vittoria ^a   Ruggeri, Marco ^c   Rodeghiero, Francesco ^c   Rambaldi, Alessandro ^a   Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BUSULFAN; HYDROXYUREA; JANUS KINASE 2;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR RISK; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS; COHORT ANALYSIS; CYTOLOGY; LEUKOCYTE; MIDDLE AGED; NUCLEOTIDE SEQUENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LEUKOCYTES; LEUKOCYTOSIS; MALE; MIDDLE AGED; PLATELET COUNT; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOCYTOSIS;

EID: 54049086618     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-153783     Document Type: Article

References (12)

1. Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med. 2005; 353:85-86.
2. Vannucchi AM, Barbui T. Thrombocytosis and thrombosis. Hematology Am Soc Hematol Educ Program. 2007;2007:363-370.
3. Tefferi A, Gangat N, Wolanskyj AP. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood. 2006;108:2493-2494.
4. Barbui T. Barosi G, Grossi A, et al. Practice guidelines tor the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89: 215-232.
5. Harrison CN. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol. 2005;130:153-165.
6. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109:2310-2313.
7. Vannucchi AM. Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21:1952-1959.
8. Pancrazzi A. Guglielmelli P, Ponziani V. et al. A sensitive detection method for MPLW515L or W515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. J Mol Diagn. 2008;10:435-441.
9. Di Nisio M, Barbui T Di Gennaro L. et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136:249-259.
10. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128: 275-290.
11. Girolami A, Tezza F, Scapin M, Vettore S, Casonato A. Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature. J Thromb Thrombolysis. 2006;21:175-178.
12. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353:33-45.